Cure My Disease

Don't miss your cure!

 Log in / Sign up

Medical records reveal clues to treating stubborn inflammatory bowel disease

NCT ID NCT07697521

Knowledge-focused Sponsor: Shanghai 10th People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study looks back at the medical records of over 1,000 people hospitalized with inflammatory bowel disease (IBD) in China. The goal is to understand the features, treatments, and outcomes of patients whose IBD does not respond well to standard therapies. By analyzing real-world data, researchers hope to identify factors linked to harder-to-treat disease and improve future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better identify which treatments work best for hard-to-treat inflammatory bowel disease.
What could go wrong
This is an observational study that looks back at existing records, so it cannot prove cause and effect. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,048 people

The number who actually took part.

Started

Jan 2020

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible patients had an established diagnosis of CD or UC based on clinical, endoscopic, radiologic, and histopathologic findings in accordance with European Crohn's and Colitis Organization guidance. Refractory IBD was defined according to the IOIBD consensus criteria. Patients were classified as having refractory IBD if they fulfilled at least one of the following criteria: failure of at least two biologic or small-molecule therapies with different mechanisms of action; recurrence after at least two surgeries in adult patients with CD; complex perianal disease; or chronic antibiotic-refractory pouchitis. Psychological factors were not included because they could not be assessed consistently in this retrospective study. Patients were excluded if they had participated in clinical trials or received investigational drugs, had concomitant malignancy, severe immunodeficiency, or other systemic autoimmune diseases, or were diagnosed with IBD-unclassified.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible patients had an established diagnosis of CD or UC based on clinical, endoscopic, radiologic, and histopathologic findings in accordance with European Crohn's and Colitis Organization guidance Exclusion Criteria: * Patients were excluded if they had participated in clinical trials or received investigational drugs, had concomitant malignancy, severe immunodeficiency, or other systemic autoimmune diseases, or were diagnosed with IBD-unclassified

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflamatory bowel disease

Contacts and locations

Locations

  • The Tenth People's Hospital of Shanghai

    Shanghai, Shanghai Municipality, 201505, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.